David Zaccardelli Sells 98,888 Shares of Verona Pharma plc (NASDAQ:VRNA) Stock

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 98,888 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $5.01, for a total transaction of $495,428.88. Following the transaction, the chief executive officer now directly owns 15,078,624 shares of the company’s stock, valued at $75,543,906.24. The trade was a 0.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

David Zaccardelli also recently made the following trade(s):

• On Monday, December 2nd, David Zaccardelli sold 3,200 shares of Verona Pharma stock. The stock was sold at an average price of $5.00, for a total transaction of $16,000.00.
• On Wednesday, November 27th, David Zaccardelli sold 23,240 shares of Verona Pharma stock. The shares were sold at an average price of $5.00, for a total value of $116,200.00.
• On Monday, November 11th, David Zaccardelli sold 2,400 shares of Verona Pharma stock. The stock was sold at an average price of $5.00, for a total value of $12,000.00.
• On Monday, November 4th, David Zaccardelli sold 94,144 shares of Verona Pharma stock. The shares were sold at an average price of $4.39, for a total value of $413,292.16.
• On Friday, November 1st, David Zaccardelli sold 46,888 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $205,369.44.
• On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $21,024.00.
• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $483,797.28.
• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $1,076,533.92.

Verona Pharma Trading Down 1.2 %

NASDAQ:VRNA opened at $38.66 on Wednesday. The business’s 50-day simple moving average is $35.03 and its 200-day simple moving average is $25.79. Verona Pharma plc has a fifty-two week low of $11.39 and a fifty-two week high of $40.76. The company has a debt-to-equity ratio of 0.93, a current ratio of 13.03 and a quick ratio of 12.88. The stock has a market capitalization of $3.09 billion, a PE ratio of -20.14 and a beta of 0.46.

Verona Pharma (NASDAQ:VRNA) last released its quarterly earnings results on Monday, November 4th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.12). The firm had revenue of $5.62 million for the quarter, compared to the consensus estimate of $2.31 million. During the same period in the previous year, the business earned ($0.18) EPS. Sell-side analysts expect that Verona Pharma plc will post -2.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Verona Pharma

Large investors have recently added to or reduced their stakes in the company. CWM LLC bought a new stake in shares of Verona Pharma in the second quarter valued at about $29,000. EMC Capital Management acquired a new stake in Verona Pharma in the 2nd quarter valued at approximately $38,000. GAMMA Investing LLC lifted its stake in Verona Pharma by 70.6% in the 3rd quarter. GAMMA Investing LLC now owns 1,336 shares of the company’s stock valued at $38,000 after acquiring an additional 553 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Verona Pharma by 25.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock worth $75,000 after acquiring an additional 529 shares during the last quarter. Finally, Legato Capital Management LLC bought a new position in shares of Verona Pharma during the 2nd quarter worth approximately $154,000. Institutional investors own 85.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Wells Fargo & Company boosted their price objective on Verona Pharma from $50.00 to $64.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Canaccord Genuity Group increased their price objective on Verona Pharma from $37.00 to $44.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. HC Wainwright boosted their target price on Verona Pharma from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, Truist Financial raised their price target on Verona Pharma from $38.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $43.83.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.